SecBot SecBot
SECBOTREPLAY Home › Report › LGVN

LGVN · Longeveron Inc

Longeveron Inc. · 8-K filed Mar 9, 2026 at 06:01 ET

At the news

BEARISHIMPACT 7/10

8-K filed Mar 9, 2026 at 06:01 ET

Longeveron Inc. filed an 8-K disclosing that board member and audit committee financial expert Richard Kender resigned due to his new role at Seres Therapeutics, causing the company to fall out of Nasdaq compliance. The company appointed Dr. Roger Hajjar to the audit committee but still lacks a financial expert, triggering a delisting notice with a plan to appoint or elect a qualified director within 180 days.

  • Richard Kender resigned from the Board and Audit Committee effective March 3, 2026, due to his appointment as Executive Chairman and Interim CEO of Seres Therapeutics.
  • His resignation caused Longeveron to no longer comply with Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three independent audit committee members, one of whom must be a financial expert.
  • The company appointed Dr. Roger Hajjar to the Audit Committee on March 4, 2026, restoring the three-member requirement but still lacking a financial expert.
  • Longeveron has a 180-day cure period to appoint or elect a director who qualifies as both independent and an audit committee financial expert.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access